Kathie Bishop | SVP and Head, Rare Disease & External Innovation |
Srdjan Stankovic | President |
Stephen Davis | CEO & Director |
Mark Johnson | VP, IR |
Brendan Teehan | EVP, COO & Head of Commercial |
Mark Schneyer | EVP & CFO |
Jay Olson | Oppenheimer |
Marc Goodman | SVB Securities |
Tazeen Ahmad | Bank of America Merrill Lynch |
Ritu Baral | Cowen and Company |
Neena Garg | Citigroup |
Gregory Renza | RBC Capital Markets |
Sumant Kulkarni | Canaccord Genuity |
Charles Duncan | Cantor Fitzgerald & Co. |
Eddie Hickman | Guggenheim Securities |
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Mr. Mark Johnson, Vice President of Investor Relations at ACADIA.